DR-494 Analysis of MYC-driven transcriptional programs and genomic mutations linked to immune checkpoint inhibitor resistance in melanoma and non-small cell lung cancer.

Through comprehensive bioinformatic analysis of datasets, the purpose of our project is to identify MYC-dependent signatures and to assess their association with resistance to immune checkpoint blockade in melanoma and non-small cell lung cancer (NSCLC). We plan to use WGS and RNAseq data from Hartwig Medical Foundation, aiming to determine crucial insights into the relationship between genomic mutations, MYC transcriptional activity, and treatment response, to finally predict which patients could benefit from immunotherapy (IO), MYC-targeted strategies or the combination of both.

Laura Soucek, Vall d’Hebron Institute of Oncology (VHIO), Spain